Login / Signup

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).

Kensuke UsukiShigeki OhtakeSumihisa HondaMitsuhiro MatsudaAtsushi WakitaYuichiro NawaKen TakaseAkio MaedaNobuo SezakiHisayuki YokoyamaSatoru TakadaDaiki HiranoTatsuki TomikawaMasahiko SumiShingo YanoHiroshi HandaShuichi OtaHiroyuki FujitaKatsumichi FujimakiAtsuko MugitaniKensuke KojimaTomohiro KajiguchiKo FujimotoNorio AsouNoriko UsuiYuichi IshikawaAkira KatsumiItaru MatsumuraHitoshi KiyoiYasushi Miyazaki
Published in: International journal of hematology (2023)
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58.9% [95% CI: 54.5-63.1%] vs 35.5% [33.3-37.8%], p < 0.0001). Women had a higher OS rate than men (5-year OS, 34% [95% CI; 31.4-36.7%] vs 27.7% [25.7-29.7%], p < 0.0001). The OS rate was lower in patients aged 40 and older than those under 40, and even lower in those over 65 (5-year OS for ages < 40, 40-64, 65-74, ≥ 75: 74.5% [95% CI; 69.3-79.0%] vs 47.5% [44.4-50.6%] vs 19.3% [16.8-22.0%] vs 7.3% [5.5-9.4%], respectively). This is the first paper to present large-scale data on survival and clinical characteristics in Japanese AML patients.
Keyphrases